Asthma: role of the angiotensin-(1-7)/Mas (MAS1) pathway in pathophysiology and therapy.
Juliana Fabiana GregórioMaria da Glória Rodrigues-MachadoRobson Augusto Souza Dos SantosIgor Antônio Carvalho-RibeiroOlivia Mendonça NunesIsabel Fusaro Aguiar OliveiraAna Victoria de Oliveira VasconcellosMaria José Campagnole-SantosGiselle Santos MagalhãesPublished in: British journal of pharmacology (2021)
The incidence of asthma is a global health problem and requires studies aimed for the development of new treatments to improve its clinical management, reducing personal and economic burdens on the health system. Therefore, the discovery of mediators that promote anti-inflammatory and pro-resolutive effects are highly desirable to improve lung function and quality of life of asthmatic patients. In that regard, experimental studies have shown that the angiotensin-(1-7)/Mas receptor (MAS1) of the renin-angiotensin system is a potential candidate for the treatment of asthma. Therefore, we have reviewed findings related to the function of the angiotensin-(1-7)/Mas pathway in regulating the processes associated with inflammation, including leukocyte influx, fibrogenesis, pulmonary dysfunction and the resolution of inflammation in asthma. Thus, a knowledge of the role of the angiotensin-(1-7)/Mas can help pave the way for the development of new treatments for this disease, which has high morbidity and mortality, through new types of experiments and clinical trials.
Keyphrases
- lung function
- chronic obstructive pulmonary disease
- cystic fibrosis
- air pollution
- angiotensin converting enzyme
- angiotensin ii
- global health
- oxidative stress
- anti inflammatory
- clinical trial
- ejection fraction
- end stage renal disease
- newly diagnosed
- allergic rhinitis
- public health
- prognostic factors
- pulmonary hypertension
- high throughput
- risk factors
- stem cells
- small molecule
- patient reported outcomes
- case control
- peripheral blood
- single cell
- bone marrow
- risk assessment
- human health
- mesenchymal stem cells
- patient reported
- phase iii
- open label
- phase ii